Annual Financials for GW Pharmaceuticals PLC ADR
Fiscal year is January-December. All values USD millions. |
2016 | 2017 | 2018 | 2019 | 2020 |
5-year trend |
Sales/Revenue
|
14.58M | 10.58M | 15.49M | 312.62M | 531.31M | |
Sales Growth |
- | -27.44% | 46.35% | 1,918.66% | 69.95% | |
Cost of Goods Sold (COGS) incl. D&A |
9.03M | 11.64M | 11.01M | 27.31M | 37.82M | |
COGS excluding D&A |
3.84M | 4.55M | 1.63M | 18.03M | 24.97M | |
Depreciation & Amortization Expense |
5.18M | 7.09M | 9.38M | 9.28M | 12.86M | |
Depreciation |
5.1M | 6.78M | 8.49M | 8.03M | - | |
Amortization of Intangibles |
87,661 | 314,865 | 892,888 | 1.25M | - | |
COGS Growth |
- | 28.94% | -5.44% | 148.09% | 38.49% | |
Gross Income |
5.56M | (1.06M) | 4.48M | 285.31M | 493.48M | |
Gross Income Growth |
- | -119.09% | 522.34% | 6,271.33% | 72.96% | |
Gross Profit Margin |
- | - | - | - | 92.88% | NA |
|
2016 | 2017 | 2018 | 2019 | 2020 |
5-year trend |
SG&A Expense |
164.13M | 188.8M | 278.63M | 408.23M | 545.65M | |
Research & Development |
141.13M | 142.87M | 133.49M | 147.28M | 206.99M | |
Other SG&A |
23.01M | 45.93M | 145.14M | 260.96M | 338.66M | |
SGA Growth |
- | 15.03% | 47.58% | 46.52% | 33.66% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | 536,177 | - | - | - | |
EBIT after Unusual Expense |
- | (536,177) | - | - | - | |
Non Operating Income/Expense |
36.13M | (6.48M) | (2.13M) | 102.27M | (4M) | |
Non-Operating Interest Income |
859,639 | 2.08M | 8.91M | 8.5M | 1.83M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
244,601 | 956,668 | 1.26M | 1.09M | 1.13M | |
Interest Expense Growth |
- | 291.11% | 31.32% | -13.12% | 3.50% | |
Gross Interest Expense |
244,601 | 956,668 | 1.26M | 1.09M | 1.13M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(121.84M) | (195.76M) | (268.62M) | (13.25M) | (55.47M) | |
Pretax Income Growth |
- | -60.67% | -37.22% | 95.07% | -318.69% | |
Pretax Margin |
- | - | - | - | -10.44% | NA |
Income Tax |
(31.83M) | (26.61M) | 4.07M | (4.19M) | 3.11M | |
Income Tax - Current Domestic |
- | 2.15M | 4.06M | - | - | |
Income Tax - Current Foreign |
1.66M | - | - | 9.55M | - | |
Income Tax - Deferred Domestic |
(2.82M) | (3.2M) | 8,785 | - | - | |
Income Tax - Deferred Foreign |
- | - | - | (9.74M) | - | |
Income Tax Credits |
30.68M | 25.56M | - | 4.01M | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(90M) | (169.15M) | (272.69M) | (9.06M) | (58.58M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(90M) | (169.15M) | (272.69M) | (9.06M) | (58.58M) | |
Net Income Growth |
- | -87.93% | -61.21% | 96.68% | -546.84% | |
Net Margin Growth |
- | - | - | - | -11.03% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(90M) | (169.15M) | (272.69M) | (9.06M) | (58.58M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(90M) | (169.15M) | (272.69M) | (9.06M) | (58.58M) | |
EPS (Basic) |
(3.99) | (6.69) | (9.61) | (0.29) | (1.87) | |
EPS (Basic) Growth |
- | -67.68% | -43.78% | 96.96% | -540.12% | |
Basic Shares Outstanding |
22.53M | 25.3M | 28.37M | 30.97M | 31.3M | |
EPS (Diluted) |
(3.99) | (6.69) | (9.61) | (0.29) | (1.87) | |
EPS (Diluted) Growth |
- | -67.68% | -43.78% | 96.96% | -540.12% | |
Diluted Shares Outstanding |
22.53M | 25.3M | 28.37M | 30.97M | 31.3M | |
EBITDA |
(153.39M) | (182.76M) | (264.77M) | (113.65M) | (39.31M) | |
EBITDA Growth |
- | -19.15% | -44.87% | 57.08% | 65.41% | |
EBITDA Margin |
- | - | - | - | -7.40% | NA |